GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » Days Inventory

HOOK (HOOKIPA Pharma) Days Inventory : 0.00 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is HOOKIPA Pharma Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). HOOKIPA Pharma's Average Total Inventories for the three months ended in Dec. 2024 was $0.00 Mil. HOOKIPA Pharma's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for HOOKIPA Pharma's Days Inventory or its related term are showing as below:

HOOK's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 177.045
* Ranked among companies with meaningful Days Inventory only.

HOOKIPA Pharma's Days Inventory stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. HOOKIPA Pharma's Inventory-to-Revenue for the three months ended in Dec. 2024 was 0.00.


HOOKIPA Pharma Days Inventory Historical Data

The historical data trend for HOOKIPA Pharma's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HOOKIPA Pharma Days Inventory Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Inventory
Get a 7-Day Free Trial - - - - -

HOOKIPA Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HOOKIPA Pharma's Days Inventory

For the Biotechnology subindustry, HOOKIPA Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Days Inventory distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Days Inventory falls into.


;
;

HOOKIPA Pharma Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

HOOKIPA Pharma's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as

Days Inventory (A: Dec. 2024 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

HOOKIPA Pharma's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:

Days Inventory (Q: Dec. 2024 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2024 ) + Total Inventories (Q: Dec. 2024 )) / count ) / Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HOOKIPA Pharma  (NAS:HOOK) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

HOOKIPA Pharma's Inventory Turnover for the three months ended in Dec. 2024 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

HOOKIPA Pharma's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


HOOKIPA Pharma Days Inventory Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


HOOKIPA Pharma Business Description

Traded in Other Exchanges
N/A
Address
350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
Executives
Reinhard Kandera director, officer: Chief Financial Officer C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag director, officer: Chief Executive Officer C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger officer: Chief Medical Officer 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters director TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky officer: Chief Medical Officer C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker officer: Chief Business Officer C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja officer: Sr. VP, Technical Development C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger officer: Sr. VP, Research C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina officer: Chief Technology Officer C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a. 10 percent owner C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016

HOOKIPA Pharma Headlines

From GuruFocus